(Q37796519)

23 August 2017

title

Radioactive antibodies: a historical review of selective targeting and treatment of cancer (English)

1 reference

23 August 2017

David M Goldenberg

1

1 reference

23 August 2017

Robert M Sharkey

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

38

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

82-93

1 reference

Targeted therapy of cancer: new prospects for antibodies and immunoconjugates

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Carcinoembryonic antigen present in human colonic neoplasms serially propagated in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Specific carcinoembryonic antigens of the human digestive system

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Novel radiolabeled antibody conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Covalent attachment of metal chelates to proteins:the stability in vivo and in vitro of the conjugate of albumin with a chelate of 111indium

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

The radioisotope contributes significantly to the activity of radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Radioimmunoconjugates in acute leukemia treatment: the future is radiant

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Radioimmunotherapy of small-volume disease of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Use of antibodies and immunoconjugates for the therapy of more accessible cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Radionuclide-antibody conjugates for single-cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Applications of single-chain variable fragment antibodies in therapeutics and diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Engineered affinity proteins for tumour-targeting applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

A novel method of 18F radiolabeling for PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

Antibodies against metal chelates

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.06.300

21 January 2018

Identifiers

DOI

10.3810/HP.2010.06.300

1 reference

23 August 2017

1 reference